Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial

被引：7

作者：

Eggermont, Alexander M. M. ^{[1
,2
,3
,4
]}

Kicinski, Michal ^{[5
]}

Blank, Christian U. ^{[6
]}

Mandala, Mario ^{[7
]}

V. Long, Georgina ^{[8
,9
]}

Atkinson, Victoria ^{[10
]}

Dalle, Stephane ^{[11
]}

Haydon, Andrew ^{[12
]}

Meshcheryakov, Andrey ^{[13
]}

Khattak, Adnan ^{[11
,14
,15
]}

Carlino, Matteo S. ^{[16
]}

Sandhu, Shahneen ^{[17
]}

Larkin, James ^{[18
]}

Puig, Susana ^{[19
,20
]}

Ascierto, Paolo A. ^{[21
]}

Rutkowski, Piotr ^{[22
]}

Schadendorf, Dirk ^{[23
,24
]}

Boers-Sonderen, Marye ^{[25
]}

Di Giacomo, Anna Maria ^{[26
,27
]}

van den Eertwegh, Alfonsus J. M. ^{[28
]}

Grob, Jean-Jacques ^{[29
]}

Gutzmer, Ralf ^{[30
]}

Jamal, Rahima ^{[31
]}

van Akkooi, Alexander C. J. ^{[32
,33
]}

Lorigan, Paul ^{[34
,35
]}

Grebennik, Dmitri ^{[36
]}

Kreplere, Clemens ^{[36
]}

Marreaud, Sandrine ^{[5
]}

Suciu, Stefan ^{[5
]}

Robert, Caroline ^{[37
,38
]}

机构：

[1] Tech Univ Munich, Comprehens Canc Ctr Munich, Munich, Germany

[2] Ludwig Maximilians Univ Munchen, Munich, Germany

[3] Princess Maxima Ctr, Utrecht, Netherlands

[4] Univ Med Ctr Utrecht, Utrecht, Netherlands

[5] EORTC Headquarters, Brussels, Belgium

[6] Netherlands Canc Inst Antoni Van Leeuwenhoek, Amsterdam, Netherlands

[7] Univ Perugia, Santa Maria Misericordia Hosp, Perugia, Italy

[8] Univ Sydney, Melanoma Inst Australia, Sydney, Australia

[9] Mater & Royal North Shore Hosp, Sydney, Australia

[10] Univ Queensland, Princess Alexandra Hosp, Brisbane, Australia

[11] Lyon Univ, HCL Canc Inst, Canc Res Ctr Lyon, Lyon, France

[12] Alfred Hosp, Melbourne, Australia

[13] Fed Med Biol Agcy, Lopukhin Fed Res & Clin Ctr Phys Chem Med, Moscow, Russia

[14] Univ Western Australia, Fiona Stanley Hosp, Perth, Australia

[15] Edith Cowan Univ, Perth, Australia

[16] Melanoma Inst Australia, Westmead & Blacktown Hosp, Sydney, NSW, Australia

[17] Peter MacCallum Canc Ctr, Melbourne, Australia

[18] Royal Marsden Hosp, London, England

[19] Univ Barcelona, Hosp Clin Barcelona, Barcelona, Spain

[20] CIBERER, Inst Salud Carlos III, Barcelona, Spain

[21] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy

[22] Mar Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[23] Univ Hosp Essen, Essen, Germany

[24] German Canc Consortium, Heidelberg, Germany

[25] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands

[26] Univ Siena, Siena, Italy

[27] Univ Hosp Siena, Ctr Immunooncol, Siena, Italy

[28] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands

[29] Aix Marseille Univ, Hop Timone, AP HM, Marseille, France

[30] Ruhr Univ Bochum, Johannes Wesling Med Ctr, Campus Minden, Minden, Germany

[31] Ctr Hosp Univ Montreal CHUM, Ctr Rech CHUM, Montreal, PQ, Canada

[32] Univ Sydney, Melanoma Inst Australia, Fac Med & Hlth, Wollstonecraft Sydney, Camperdown, NSW, Australia

[33] Royal Prince Alfred Hosp, Inst Acad Surg, Camperdown, NSW, Australia

[34] Univ Manchester, Div Canc Sci, Manchester, England

[35] Christie NHS Fdn Trust, Manchester, England

[36] Merck & Co Inc, Rahway, NJ USA

[37] Gustave Roussy Canc Campus Grand Paris, Villejuif, France

[38] Univ Paris Saclay, Villejuif, France

来源：

EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷

关键词：

Anti-PD1; Anti-PDL1; Clinical trial; Immune checkpoint inhibitors; Melanoma; Phase; 3; Immunotherapy; Pembrolizumab; Adjuvant treatment; METASTASIS-FREE SURVIVAL; DOUBLE-BLIND; COMPLETE RESECTION; IPILIMUMAB; NIVOLUMAB;

D O I：

10.1016/j.ejca.2024.114327

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the previously reported primary analyses of this phase 3 trial, 12 months of adjuvant pembrolizumab resulted in significantly longer recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) than placebo in patients with resected high risk stage III melanoma. Stability of these benefits when the median follow-up was 3.5 and 5 years was published. Here we report results with a longer follow-up. Methods: We randomized 1019 patients to receive pembrolizumab 200 mg or placebo, intravenously every 3 weeks for a total of 18 doses. RFS in the overall population and in the subgroup of patients with melanoma positive for the PD-1 ligand (PD-L1) were co-primary endpoints. DMFS in these two populations was a secondary and progression/recurrence-free survival 2 (PRFS2) an exploratory endpoint. Results: The median follow-up was 6.9 years. In the overall intention-to-treat population, RFS was longer in the pembrolizumab group than in the placebo group (HR 0.63, 95 % CI 0.53 to 0.74). RFS at 7 years was 50 % (95 % CI 46 % to 55 %) in the pembrolizumab and 36 % (95 % CI 32 % to 41 %) in the placebo group. Positive effects were present both for loco-regional recurrences and distant metastases, and across substages IIIA-IIIB-IIIC, and PD-L1 positive and PD-L1 negative as well as for BRAF mutant and BRAF wild type populations. DMFS was longer in the pembrolizumab group than in the placebo group (HR 0.64, 95 % CI 0.54 to 0.76). DMFS at 7 years was 54 % (95 % CI 50 % to 59 %) in the pembrolizumab and 42 % (95 % CI 37 % to 46 %) in the placebo group. PRFS2 was longer in the pembrolizumab group than in the placebo group (HR 0.69, 95 % CI 0.57 to 0.84). PRFS2 at 7 years was 61 % (95 % CI 57 % to 66 %) in the pembrolizumab and 53 % (95 % CI 49 % to 57 %) in the placebo group. Conclusions: The 7-year analysis of adjuvant therapy with pembrolizumab demonstrated a sustained improvement in the long-term RFS, DMFS and PRFS2 compared with placebo in patients with resected stage III melanoma.

引用

页数：10

共 50 条

[41] Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial
Luke, J.
Rutkowski, P.
Queirolo, P.
Del Vecchio, M.
Mackiewicz, J.
Sileni, V. Chiarion
De la CruzMerino, L.
Khattak, M. A.
Schadendorf, D.
Long, G. V.
Ascierto, P. A.
Mandala, M.
De Galitiis, F.
Sondak, V.
Scolyer, R. A.
Kirkwood, J. M.
Chen, K.
Ibrahim, N.
Ahsan, S.
Eggermont, A. M. M.
ANNALS OF ONCOLOGY, 2021, 32 : S1314 - S1315
[42] Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC): KEYNOTE-522 Korean subgroup analysis
Park, Y. H.
Im, S-A.
Ahn, J-H.
Kim, M. H.
Cortes, J.
Dent, R. A.
Pusztai, L.
McArthur, H. L.
Kummel, S.
Denkert, C.
O'Shaughnessy, J.
Mouret-Reynier, M-A.
Ferreira, M. I. R.
Cortes, M. Gion
Boileau, J-F.
Hui, R.
Zhu, Y.
Pan, W.
Karantza, V. V.
Schmid, P.
ANNALS OF ONCOLOGY, 2023, 34 : S1467 - S1468
[43] Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre double-blind, randomised, phase 3 trial
Long, Georgina, V
Luke, Jason J.
Khattak, Muhammad A.
Merino, Luis de la Cruz
Del Vecchio, Michele
Rutkowski, Piotr
Spagnolo, Francesco
Mackiewicz, Jacek
Chiarion-Sileni, Vanna
Kirkwood, John M.
Robert, Caroline
Grob, Jean-Jacques
de Galitiis, Federica
Schadendorf, Dirk
Carlino, Matteo S.
Mohr, Peter
Dummer, Reinhard
Gershenwald, Jeffrey E.
Yoon, Charles H.
Wu, Xi Lawrence
Fukunaga-Kalabis, Mizuho
Krepler, Clemens
Eggermont, Alexander M. M.
Ascierto, Paolo A.
LANCET ONCOLOGY, 2022, 23 (11): : 1378 - 1388
[44] Adjuvant pembrolizumab versus placebo in resected high- risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study
Khattak, Muhammad A.
Luke, Jason J.
Long, Georgina V.
Ascierto, Paolo A.
Rutkowski, Piotr
Schadendorf, Dirk
Robert, Caroline
Grob, Jean-Jacques
Merino, Luis de la Cruz
Del Vecchio, Michele
Spagnolo, Francesco
Mackiewicz, Jacek
Chiarion-Sileni, Vanna
Carlino, Matteo S.
Mohr, Peter
De Galitiis, Federica
Ross, Merrick I.
Eroglu, Zeynep
Chen, Ke
Jiang, Ruixuan
Fukunaga-Kalabis, Mizuho
Krepler, Clemens
Eggermont, Alexander M. M.
Kirkwood, John M.
EUROPEAN JOURNAL OF CANCER, 2022, 176 : 207 - 217
[45] Neoadjuvant and Adjuvant Pembrolizumab for the Treatment of Early-Stage Resectable Non-small Cell Lung Cancer An Editorial Regarding the Interim Data Analysis of the KEYNOTE-671 Phase III Trial of Neoadjuvant and Adjuvant Pembrolizumab
Jessica M. Ruck
Stephen R. Broderick
Annals of Surgical Oncology, 2024, 31 : 4 - 5
[46] Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial
Eggermont, Alexander M. M.
Suciu, Stefan
Santinami, Mario
Testori, Alessandro
Kruit, Wim H. J.
Marsden, Jeremy
Punt, Cornelis J. A.
Sales, Francois
Gore, Martin
MacKie, Rona
Kusic, Zvonko
Dummer, Reinhard
Hauschild, Axel
Musat, Elena
Spatz, Alain
Keilholz, Ulrich
LANCET, 2008, 372 (9633): : 117 - 126
[47] Neoadjuvant and Adjuvant Pembrolizumab for the Treatment of Early-Stage Resectable Non-small Cell Lung Cancer An Editorial Regarding the Interim Data Analysis of the KEYNOTE-671 Phase III Trial of Neoadjuvant and Adjuvant Pembrolizumab
Ruck, Jessica M.
Broderick, Stephen R.
ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : 4 - 5
[48] Adjuvant therapy with pegylated interferon α-2b versus observation in resected stage III melanoma:: final results of EORTC 18991, a randomised phase 3 trial
Eggermont, A. M. M.
Suciu, S.
Santinami, M.
Testori, A.
Kruit, W.
Marsden, J.
Punt, C. J. A.
Sales, F.
Gore, M.
Mckie, R.
Kusic, V.
Dummer, R.
Musat, E.
Spatz, A.
Keilholz, U.
PIGMENT CELL & MELANOMA RESEARCH, 2008, 21 (02) : 290 - 290
[49] Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial (vol 16, pg 522, 2015)
Eggermont, A. M. M.
Chiarion-Sileni, V
Grob, J-J
LANCET ONCOLOGY, 2015, 16 (06): : E262 - E262
[50] Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma
Eggermont, Alexander M. M.
Suciu, Stefan
Testori, Alessandro
Santinami, Mario
Kruit, Wim H. J.
Marsden, Jeremy
Punt, Cornelis J. A.
Sales, Francois
Dummer, Reinhard
Robert, Caroline
Schadendorf, Dirk
Patel, Poulam M.
de Schaetzen, Gaetan
Spatz, Alan
Keilholz, Ulrich
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (31) : 3810 - 3818

← 1 2 3 4 5 →